Immune Therapeutics, Inc. filed its 10-K on Apr 10, 2023 for the period ending Dec 31, 2022. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0417 USD | +24.60% | +19.14% | -42.88% |
20/05 | Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
16/04 | Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-42.88% | 3.49M | |
+16.86% | 122B | |
+22.03% | 116B | |
+22.18% | 27.03B | |
-21.29% | 20.36B | |
-16.89% | 16.43B | |
-18.31% | 15.91B | |
-44.74% | 15.6B | |
+62.64% | 14.94B | |
+3.13% | 13.59B |
- Stock Market
- Equities
- BTAX Stock
- News Biostax Corp.
- Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt